1-5 of 5
Yannis Morel
Close
Sort by
Journal Articles

IPH6501 Is a Novel NKp46-Targeting Tetraspecific Antibody-Based Natural Killer Cell Engager Therapeutic (ANKET) Armed with a Non-Alpha IL-2 Variant and Developed for the Treatment of CD20-Positive Malignancies

Olivier Demaria, Guillaume Habif, François Le Floch, Laura Chiossone, Romain Remark, Marie Vetizou, Nadia Maurel, Laurent Gauthier, Yannis Morel, Carine Paturel, Eric Vivier, Pascale Andre
Journal: Blood
Blood (2022) 140 (Supplement 1): 11559.
https://doi.org/10.1182/blood-2022-163561
Published: 2022
Journal Articles

The Novel Trifunctional Anti-BCMA NK Cell Engager SAR'514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Alexandre Tang, Laurent Gauthier, Jochen Beninga, Benjamin Rossi, Nicolas Gourdin, Audrey Blanchard-Alvarez, Céline Amara, Jacqueline Courta, Alexandra Basset, Dorothee Bourges, Alexandre Desjonqueres, Emmanuelle Menoret, Catherine Pellat-Deceunynck, Philippe Moreau, Yannis Morel, Marielle Chiron, Angela Virone-Oddos, Eric Vivier
Journal: Blood
Blood (2022) 140 (Supplement 1): 9985–9986.
https://doi.org/10.1182/blood-2022-166187
Published: 2022
Journal Articles

Lirilumab Enhances Anti-Tumor Efficacy of Elotuzumab

Caroline Sola, PhD, Mathieu Blery, PhD, Cécile Bonnafous, PhD, Elodie Bonnet, Nicolas Fuseri, Robert F Graziano, PhD, Yannis Morel, PhD, Pascale André, PhD
Journal: Blood
Blood (2014) 124 (21): 4711.
https://doi.org/10.1182/blood.V124.21.4711.4711
Published: 2014
Journal Articles

Synergistic Action of the Human Inhibitory KIR Antibody IPH2102, and the Human CD38 Antibody Daratumumab to Enhance the Lysis of Primary Multiple Myeloma (MM) Cells in the Bone Marrow Mononuclear Cells (MNCs) From Myeloma Patients

Inger S. Nijhof, MD, Michel de Weers, PhD, Pascale Andre, PhD, Berris van Kessel, Henk M. Lokhorst, MD, Paul W.H.I. Parren, PhD, Yannis Morel, PhD, Tuna Mutis, MD PhD
Journal: Blood
Blood (2011) 118 (21): 1865.
https://doi.org/10.1182/blood.V118.21.1865.1865
Published: 2011
Journal Articles

Plasmacytoid dendritic cell–derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists

Deepa Rajagopal, Carine Paturel, Yannis Morel, Satoshi Uematsu, Shizuo Akira, Sandra S. Diebold
Journal: Blood
Blood (2010) 115 (10): 1949–1957.
https://doi.org/10.1182/blood-2009-08-238543
Published: 2010
Includes: Supplemental data